ClinicalTrials.gg
Active, not recruitingNCT02386800Updated Oct 19, 2026

CINC424A2X01B Rollover Protocol

A Phase 4 interventional study of ruxolitinib and panobinostat in Primary Myelofibrosis, Polycythemia Vera and Graft Versus Host Disease, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 97 sites in 25 countries. Open to participants aged 1 Month to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Updated Oct 19, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
279
Allocation
Not applicable
Ages
1 Month to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
4th of 50
279 · median 45
Started
2015
with 3 others
Phase 4
4 of 50
1 open now
Primary completion
2032-04
later than 14 of 14 live
Registered
22nd of 50
by date
Lead sponsor
11 of 50
Novartis Pharmaceuticals

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 4th largest by enrollment, is one of 4 that started in 2015, is one of 4 in phase 4, reaches primary completion later than 14 of the 14 other live ones, and was the 22nd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 1 Month to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.

Read the detailed description

This roll-over protocol allows patients from multiple protocols, who are still receiving clinical benefit, to continue their treatment in one study that covers multiple indications. The population for the roll-over study should be consistent with the population defined in the parent studies. The primary eligibility criteria for a patient to enter the roll-over protocol is the participation and completion of a Novartis or Incyte study with ruxolitinib monotherapy or combination of ruxolitinib and panobinostat. Efficacy parameters will not be measured; however safety data and an evaluation of clinical benefit will be collected.

03

Conditions studied

  • Primary Myelofibrosis
  • Polycythemia Vera
  • Graft Versus Host Disease
  • Acute Myeloid Leukemia
  • Thalassemia

Keywords

  • Myelofibrosis
  • MF
  • Polycythemia vera
  • PV
  • Acute Graft versus Host Disease
  • aGvHD
  • Chronic Graft versus Host Disease
  • cGvHD
  • Acute Myeloid Leukemia
  • AML
  • Thalassemia
  • Ruxolitinib
  • INC424
  • Panobinostat
  • LBH589
04

Who can participate

Ages eligible
1 Month to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  1. Patient is currently enrolled in a Novartis GDD or GMA-sponsored or Incyte-sponsored clinical study, are receiving either ruxolitinib or combination of ruxolitinib and panobinostat, and fulfilled all of the requirements of the parent protocol.
  2. Patient is currently benefiting from the treatment with ruxolitinib monotherapy or combination of ruxolitinib and panobinostat, as determined by the investigator
  3. Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements
  4. Patient currently has no evidence of progressive disease, as determined by the investigator, following previous treatment with ruxolitinib or combination of ruxolitinib and panobinostat

Key Exclusion criteria:

  1. Patient has been permanently discontinued from study treatment in the parent study due to any reason.
  2. Patient's indication is currently approved and reimbursed in the corresponding country for ruxolitinib monotherapy or combination of ruxolitinib and panobinostat.
  3. Pregnant or nursing (lactating) women.
  4. Female patients of (e.g. are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective , throughout the study and for up to 30 days after stopping study treatment.

Other protocol-defined Inclusion / Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Ruxolitinib monotherapy or ruxolitinib plus panobinostat in combination

    All participants will receive either ruxolitinib monotherapy or ruxolitinib in combination with panobinostat, at the same dose/schedule that they were taking in the parent study.

    Drug: ruxolitinib · Drug: panobinostat

Interventions

  • ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study

    Also known as: INC424, Jakavi

  • panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study

    Also known as: LBH589, Farydak

06

What researchers measure

Primary outcomes

  1. Incidence and severity of AEs and SAEs

    The incidence of treatment-emergent AEs and SAEs (new or worsening from baseline) will be summarized by system organ class and/or preferred term, severity (based on CTCAE grades).

    Time frame: 12 years

Secondary outcomes

  1. Percentage of participants with clinical benefit as assessed by the investigator at scheduled visits.

    The analysis of clinical benefit will be descriptive only and cannot be compared to efficacy results of other studies. In addition, as clinical benefit was only added in protocol amendment 1, it may not be available for all participants.

    Time frame: 12 years

  2. Incidence and severity of AEs and SAEs by treatment group

    AEs and SAEs for participants in the Safety group will be listed and summarized by treatment group (ruxolitinib monotherapy / ruxolitinib + panobinostat combination)

    Time frame: 12 years

07

Study locations

97 sites
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
  • Novartis Investigative Site
    Wooloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Bedford Park, South Australia 5041, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Franston, Victoria 3199, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6000, Australia
  • Novartis Investigative Site
    St Leonards, 2065, Australia
  • Novartis Investigative Site
    Leuven, Vlaams Brabant 3000, Belgium
  • Novartis Investigative Site
    Antwerp, 2020, Belgium
  • Novartis Investigative Site
    Bruges, 8000, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Toronto, Ontario M5G 1X8, Canada
  • Novartis Investigative Site
    Santiago, RM 7500922, Chile
  • Novartis Investigative Site
    Viña del Mar, Valparaiso 2540364, Chile
  • Novartis Investigative Site
    Santiago, 8420383, Chile
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Pátrai, 265 04, Greece
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Budapest, 1097, Hungary
  • Novartis Investigative Site
    Kaposvár, 7400, Hungary
  • Novartis Investigative Site
    Kecskemét, 6001, Hungary
  • Novartis Investigative Site
    Szeged, H 6725, Hungary
  • Novartis Investigative Site
    Szombathely, 9700, Hungary
  • Novartis Investigative Site
    Pune, Maharashtra 411004, India
  • Novartis Investigative Site
    Afula, 1834111, Israel
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    San Giovanni Rotondo, FG 71013, Italy
  • Novartis Investigative Site
    Florence, FI 50134, Italy
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Milan, MI 20132, Italy
  • Novartis Investigative Site
    Milan, MI 20162, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Palermo, PA 90146, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Reggio Calabria, RC 89124, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Orbassano, TO 10043, Italy
  • Novartis Investigative Site
    Varese, VA 21100, Italy
  • Novartis Investigative Site
    Naples, 80138, Italy
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4538511, Japan
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4668560, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608648, Japan
  • Novartis Investigative Site
    Isehara, Kanagawa 2591193, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Bunkyo Ku, Tokyo 1138677, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Osaka, 5458586, Japan
  • Novartis Investigative Site
    Beirut, 113-0236, Lebanon
  • Novartis Investigative Site
    Monterrey, Nuevo León 64718, Mexico
  • Novartis Investigative Site
    Gliwice, Silesian Voivodeship 44-101, Poland
  • Novartis Investigative Site
    Wroclaw, 50-367, Poland
  • Novartis Investigative Site
    Lisbon, 1099-023, Portugal
  • Novartis Investigative Site
    Lisbon, 1649-035, Portugal
  • Novartis Investigative Site
    Moscow, 125167, Russia
  • Novartis Investigative Site
    Moscow, 125284, Russia
  • Novartis Investigative Site
    Moscow, 129110, Russia
  • Novartis Investigative Site
    Petrozavodsk, 185019, Russia
  • Novartis Investigative Site
    Saint Petersburg, 197022, Russia
  • Novartis Investigative Site
    Pretoria, Gauteng 0181, South Africa
  • Novartis Investigative Site
    Soweto, Gauteng 2013, South Africa
  • Novartis Investigative Site
    Cape Town, Western 7800, South Africa
  • Novartis Investigative Site
    Pretoria, 0027, South Africa
  • Novartis Investigative Site
    Seoul, 03080, South Korea
  • Novartis Investigative Site
    Seoul, 03722, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Barcelona, Catalonia 08003, Spain
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Salamanca, 37007, Spain
  • Novartis Investigative Site
    Huddinge, SE-14186, Sweden
  • Novartis Investigative Site
    Luleå, 971 80, Sweden
  • Novartis Investigative Site
    Lund, 221 85, Sweden
  • Novartis Investigative Site
    Uddevalla, 451 80, Sweden
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Istanbul, Fatih 34093, Turkey (Türkiye)
  • Novartis Investigative Site
    Kayseri, Melikgazi 38039, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Sihhiye Altindag 06230, Turkey (Türkiye)
  • Novartis Investigative Site
    Izmir, 35100, Turkey (Türkiye)
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2015 (actual). Primary completion is estimated for Apr 2032, 205 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2015
First posted
Mar 12, 2015
StartActual
Mar 5, 2015
Primary completionEst.
Apr 5, 2032
CompletionEst.
Apr 5, 2032
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Show 1 removed
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    1 site added, 1 site removed
    Show site
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Show 1 removed
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02386800
Responsible party
Sponsor
First posted
Mar 12, 2015
Start date
Mar 5, 2015
Primary completion
Apr 5, 2032 (estimated)
Completion
Apr 5, 2032 (estimated)
Last update
Oct 19, 2026

Study contacts

Novartis Pharma, A.G
study director · Novartis Pharma, A.G.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ruxolitinib · Panobinostat

Start the discussion